During the treatment of IL-6 antagonist tocilizumab against COVID-19, it may lead to the pro-inflammatory effect of cells that do not express IL-6 receptor, resulting in ineffective disease treatment.78 Another clinical trial of tocilizumab showed a significant reduction of mortality in 28 day.79 Tofacitinib, as a JAK1 and JAK3 inhibitor, simultaneously regulates the effect of IL-6, reduces the release of cytokines from Th1 and Th17, and reduces the risk of death and respiratory failure.80 Canakinumab, an anti-IL-1β antibody, resulting 16% patients suffered with serious adverse events. This evidence concerns the gene IL6 and respiratory failure.